Trust Point Inc. Raises Stock Position in Stryker Corporation $SYK

Trust Point Inc. increased its position in shares of Stryker Corporation (NYSE:SYK) by 681.9% in the 2nd quarter, HoldingsChannel reports. The fund owned 13,480 shares of the medical technology company’s stock after acquiring an additional 11,756 shares during the period. Trust Point Inc.’s holdings in Stryker were worth $4,244,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of SYK. Norges Bank acquired a new position in shares of Stryker during the fourth quarter worth $1,822,272,000. Auto Owners Insurance Co grew its stake in Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after buying an additional 2,906,448 shares during the last quarter. Wellington Management Group LLP raised its stake in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after acquiring an additional 1,146,998 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of Stryker by 241.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,555,638 shares of the medical technology company’s stock worth $511,167,000 after acquiring an additional 1,100,673 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Royal Bank Of Canada lowered their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Wolfe Research set a $375.00 price objective on shares of Stryker in a report on Friday, July 31st. Wells Fargo & Company cut their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. reduced their target price on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $386.28.

Insider Transactions at Stryker

In related news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is currently owned by company insiders.

Stryker Price Performance

NYSE:SYK opened at $338.85 on Friday. The firm’s fifty day moving average is $320.11 and its two-hundred day moving average is $334.13. The firm has a market cap of $129.97 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 2.15 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.